UY37687A - Composiciones veterinarias para uso en tratamiento de mastitis y métodos asociados - Google Patents

Composiciones veterinarias para uso en tratamiento de mastitis y métodos asociados

Info

Publication number
UY37687A
UY37687A UY0001037687A UY37687A UY37687A UY 37687 A UY37687 A UY 37687A UY 0001037687 A UY0001037687 A UY 0001037687A UY 37687 A UY37687 A UY 37687A UY 37687 A UY37687 A UY 37687A
Authority
UY
Uruguay
Prior art keywords
mixed
sol
gel polymer
compound
methods
Prior art date
Application number
UY0001037687A
Other languages
English (en)
Inventor
Sumitra Rajagopalan
Lee Brown Christina
James Sheehan Derek
Mark Heimlich John
Todd Foster
Ellis Price Jeffrey
Alexandre Therrien
Oscar Suarez
Nicholas Cunningham
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of UY37687A publication Critical patent/UY37687A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos mixtos de polímero de sol-gel con quitosano, polímero hidrófilo, polisiloxano y agente de gelificación. El compuesto mixto de polímero de sol-gel puede formar sello duradero o sólido fuerte en respuesta a uno o más estímulos fisiológicos. Usos médicos y veterinarios del compuesto mixto, particularmente, métodos y sistemas de suministro para reducir o prevenir la incidencia de trastorno mamario en animal lechero. Métodos y composiciones de compuesto mixto de polímero de sol-gel para crear una barrera física en superficie del pezón o en canal del pezón o cisterna de animal no humano para tratamiento profiláctico de trastornos mamarios.
UY0001037687A 2017-04-20 2018-04-19 Composiciones veterinarias para uso en tratamiento de mastitis y métodos asociados UY37687A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487601P 2017-04-20 2017-04-20
US201862652992P 2018-04-05 2018-04-05

Publications (1)

Publication Number Publication Date
UY37687A true UY37687A (es) 2018-11-30

Family

ID=62116628

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037687A UY37687A (es) 2017-04-20 2018-04-19 Composiciones veterinarias para uso en tratamiento de mastitis y métodos asociados

Country Status (8)

Country Link
US (1) US11446324B2 (es)
EP (1) EP3612155A1 (es)
JP (1) JP7123971B2 (es)
CN (1) CN110536679B (es)
AU (1) AU2018254458A1 (es)
CA (1) CA3057856A1 (es)
UY (1) UY37687A (es)
WO (1) WO2018195237A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017120656A1 (de) * 2017-09-07 2019-03-07 Gea Farm Technologies Gmbh Verfahren zur Reduzierung der tierindividuellen Milchproduktion von milchgebenden Tieren
WO2019108747A1 (en) * 2017-12-01 2019-06-06 Zoetis Services Llc Hydrogel compositions and uses thereof
CN110124105B (zh) * 2019-04-15 2021-10-29 杭州电子科技大学 可调控凝胶-溶胶相变温度的生物3d打印墨水制备方法
US11945935B2 (en) 2019-05-08 2024-04-02 Saint-Gobain Performance Plastics Corporation Hydrophilic polymer compositions
CN112472659B (zh) * 2019-09-12 2022-08-16 中科微针（北京）科技有限公司 一种缓释微针贴片及其制备方法
CN115003626A (zh) * 2019-12-20 2022-09-02 威利纳米有限公司 纳米结构二元凝胶组合物及其用途
EP4164561A4 (en) * 2020-06-11 2024-07-10 Aescula Tech Inc CONTROLLED INJECTION DEVICE FOR DIFFERENT MATERIAL PROPERTIES
CN112603991A (zh) * 2020-12-22 2021-04-06 西安臻迈医疗科技有限公司 一种用于修复宫颈糜烂的凝胶及其制备方法
GB202107976D0 (en) * 2021-06-03 2021-07-21 Norbrook Lab Ltd Sol-gel compositions for veterinary use
CN114748495B (zh) * 2022-05-18 2023-02-03 广东温氏大华农生物科技有限公司 一种油水双溶的兽用林可大观复方制剂及其制备方法和应用
CN115990134B (zh) * 2022-11-08 2024-05-10 四川大学华西医院 一种可注射水凝胶/纳米凝胶载药缓释体系及其制备方法和用途
CN116082713B (zh) * 2022-12-06 2024-03-01 浙江工业大学 一种pH/温度双重响应智能水凝胶及其制备方法
CN116370497B (zh) * 2023-05-10 2024-08-16 塔里木大学 一种宠物专用伤口护理复合凝胶敷料及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0076068A3 (en) * 1981-09-25 1985-05-15 Beecham Group Plc Intramammary veterinary compositions and method for their use
ATE244584T1 (de) 1995-01-16 2003-07-15 Baxter Int Selbsttragende flächengebilde aus vernetztem fibrin zur hemmung von postoperativen adhäsionen
CA2274796C (en) 1996-12-18 2006-12-05 Bimeda Research & Development Limited Antiinfective free intramammary veterinary composition
CA2212300A1 (en) 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
ES2491866T3 (es) 1999-11-15 2014-09-08 Piramal Healthcare (Canada) Limited Disolución biopolimérica acuosa autogelificante controlada por la temperatura y dependiente del pH
US20030060414A1 (en) 2001-09-10 2003-03-27 Mchardy Nicholas Bio-security system
WO2004032899A1 (en) * 2002-10-08 2004-04-22 Orchid Chemicals & Pharmaceuticals Ltd. Antibiotic formulation for intramammary administration in milking animals
US20040197422A1 (en) * 2002-12-20 2004-10-07 Pfizer Inc Veterinary compositions for treating mastitis
EP1718237A1 (en) 2004-02-02 2006-11-08 Bimeda Research And Development Limited A method and device for treating a teat canal of an animal
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
US9205046B2 (en) 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Enhanced stability of inverse thermal gelling composite hydrogels
NZ549249A (en) 2006-08-18 2009-10-30 Univ Massey Methods for reducing the incidence of mastitis by administration of keratin
KR20130119520A (ko) 2006-10-10 2013-10-31 위스콘신 얼럼나이 리서어치 화운데이션 유방내 유두 봉합제 및 숙성된 치즈에서 시각적 결함을 감소 또는 저하시키기 위해 이를 사용하는 방법
US9034348B2 (en) 2006-12-11 2015-05-19 Chi2Gel Ltd. Injectable chitosan mixtures forming hydrogels
CN102125516B (zh) * 2010-01-13 2014-03-26 北京大学 温敏型原位凝胶药物组合物
JP5690398B2 (ja) * 2010-04-14 2015-03-25 メンリッケ・ヘルス・ケア・アーベー 抗菌性ゲル
GB201113606D0 (en) 2011-08-05 2011-09-21 Norbrook Lab Ltd Dual chamber syringe
EP2922581B1 (en) * 2012-10-25 2017-03-15 Mdt Int'l S.A. Mucoadhesive compositions comprising hyaluronic acid and chitosan for topical application
CN104981516B (zh) * 2012-12-05 2017-09-15 丹麦科技大学 包含离子型超分子结构体的介电型电活性聚合物
CA2902396A1 (en) * 2013-03-15 2014-09-18 Smith & Nephew Plc Wound dressing sealant and use thereof
EP3046605B1 (en) 2013-09-16 2019-01-09 Zoetis Services LLC Assembly for sequentially delivering substances, and associated methods
MX2018005547A (es) 2015-11-03 2018-11-09 Zoetis Services Llc Compuestos polimericos sol-gel y sus usos.
BR112018068794A2 (pt) * 2016-03-18 2019-04-09 Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food composição para a prevenção de infecção intramamária e método de prevenção de infecção intramamária

Also Published As

Publication number Publication date
CN110536679A (zh) 2019-12-03
AU2018254458A1 (en) 2019-10-17
EP3612155A1 (en) 2020-02-26
WO2018195237A1 (en) 2018-10-25
US11446324B2 (en) 2022-09-20
JP2020517344A (ja) 2020-06-18
CA3057856A1 (en) 2018-10-25
CN110536679B (zh) 2023-03-31
JP7123971B2 (ja) 2022-08-23
US20180303866A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
UY37687A (es) Composiciones veterinarias para uso en tratamiento de mastitis y métodos asociados
UY36973A (es) Compuestos poliméricos sol-gel y sus usos
PH12016502323A1 (en) Combination, composition, and method of administering the combination or composition to animals
CL2019003589A1 (es) Derivado de n2,n4-difenilpirimidin-2,4-diamina, método para la preparación del mismo, y una composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o tratamiento de cáncer.
MX2017005721A (es) Composicion veterinaria masticable agradable al paladar.
CL2015002319A1 (es) Dispositivo y sistema para el tratamiento de peces.
EP3207931A3 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
CL2018000033A1 (es) Composición para destapar una nariz tapada que tiene actividad antiviral.
CL2017001026A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención.
MX2019005141A (es) Efecto protector de dmpc, dmpg, dmpc/dmpg, lisopg y lisopc contra fármacos que causan canalopatías.
BR112017005209A2 (pt) compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112021017878A2 (pt) Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação
CO2017003263A2 (es) Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
WO2016040814A3 (en) Disulfide polymers and methods of use
Lopez-Garcia et al. Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of Gram-positive bacterial infections
AR104541A1 (es) Formulación de hidrogel con adhesión moderada
RU2018135961A (ru) Способ ускорения инволюции и предотвращения инфекции молочной железы дойного животного при запуске
BR112018015624A2 (pt) forma de dosagem oral de película de loxapina
WO2015011653A9 (en) pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM
WO2019035143A3 (en) Medicated honey and method of preparation thereof
AR111482A1 (es) Composiciones veterinarias para uso en tratamiento de mastitis y métodos asociados
CL2019003600A1 (es) Composición veterinaria intramamaria.
Directorate RUMA adopts European Medicines Agency’s list of highest priority antibiotics
IT201700075549U1 (it) Dispositivo per aumentare la detersione del sistema endodontico nei denti umani mediante l’utilizzo di ultrasuoni.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231103